EP1194171A2 - Materiaux hydrogels produisant du monoxyde d'azote - Google Patents

Materiaux hydrogels produisant du monoxyde d'azote

Info

Publication number
EP1194171A2
EP1194171A2 EP00959750A EP00959750A EP1194171A2 EP 1194171 A2 EP1194171 A2 EP 1194171A2 EP 00959750 A EP00959750 A EP 00959750A EP 00959750 A EP00959750 A EP 00959750A EP 1194171 A2 EP1194171 A2 EP 1194171A2
Authority
EP
European Patent Office
Prior art keywords
macromer
regions
region
tissue
macromer composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00959750A
Other languages
German (de)
English (en)
Inventor
Jennifer L. Hill-West
Kristyn Simcha Bohl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William Marsh Rice University
Original Assignee
William Marsh Rice University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Marsh Rice University filed Critical William Marsh Rice University
Publication of EP1194171A2 publication Critical patent/EP1194171A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne des hydrogels produisant du monoxyde d'azote (NO), de préférence photopolymérisables et biodégradables, pouvant libérer des quantités physiologiques de NO sur une durée prolongée, que l'on applique sur des sites ou à un patient nécessitant l'application de ce type de matériau pour le traitement de troubles comme la resténose, la thrombose, l'asthme, la cicatrisation, l'arthrite, la dysérection ou autres, dans lesquels le NO joue un rôle important. En règle générale, les hydrogels sont constitués de macromères, qui comprennent de préférence des zones biodégradables, et des groupes liés aux macromères sont libérés in situ, élevant ou modulant les niveaux de NO là où le traitement est requis. Les macromères peuvent former une homo ou hétéro-dispersion ou solution, polymérisée de manière à donner un matériau hydrogel qui, dans le dernier cas, peut être un réseau à semi-interpénétration ou à interpénétration. Les composés destinés à être libérés peuvent être physiquement emprisonnés, liés de façon covalente ou ionique au macromère, ou faire partie intégrante du matériau polymère. L'hydrogel peut être formé par réticulation ionique et/ou covalente. D'autres agents actifs (par exemple, thérapeutiques, prophylactiques ou diagnostiques) peuvent également être incorporés au matériau polymère.
EP00959750A 1999-09-02 2000-09-01 Materiaux hydrogels produisant du monoxyde d'azote Withdrawn EP1194171A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15205499P 1999-09-02 1999-09-02
US152054P 1999-09-02
PCT/US2000/024058 WO2001015738A2 (fr) 1999-09-02 2000-09-01 Materiaux hydrogels produisant du monoxyde d'azote

Publications (1)

Publication Number Publication Date
EP1194171A2 true EP1194171A2 (fr) 2002-04-10

Family

ID=22541347

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00959750A Withdrawn EP1194171A2 (fr) 1999-09-02 2000-09-01 Materiaux hydrogels produisant du monoxyde d'azote

Country Status (7)

Country Link
EP (1) EP1194171A2 (fr)
AU (1) AU7101600A (fr)
CA (1) CA2353531A1 (fr)
CZ (1) CZ20011899A3 (fr)
IL (1) IL143305A0 (fr)
MX (1) MXPA01005338A (fr)
WO (1) WO2001015738A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052711B2 (en) 1999-09-02 2006-05-30 Rice University Nitric oxide-producing hydrogel materials
US7279176B1 (en) 1999-09-02 2007-10-09 Rice University Nitric oxide-producing hydrogel materials
WO2001087312A1 (fr) * 2000-05-18 2001-11-22 Genetix Pharmaceuticals, Inc. Utilisation de polymeres polyethyleneglycols (peg) dans la stimulation de l'angiogenese
JP4841066B2 (ja) * 2000-09-01 2011-12-21 ライスユニバーシティ 酸化窒素生成ヒドロゲル物質
CA2833997C (fr) 2001-09-05 2017-09-26 Geno Llc Methode et appareil de production d'oxyde nitrique
WO2003092700A1 (fr) 2002-04-29 2003-11-13 Gmp Oxycell, Inc. Inositol pyrophosphates et procede d'utilisation desdits composes
CA2487720A1 (fr) * 2002-06-03 2003-12-11 Alnis Biosciences, Inc. Agent therapeutique contenant des nanoarticles polymeriques
US7618594B2 (en) 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
AU2005277397B2 (en) 2004-08-18 2011-08-25 VERO Biotech LLC. Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
EP3556401A1 (fr) 2005-05-27 2019-10-23 The University of North Carolina at Chapel Hill Particules libérant de l'oxyde nitrique pour thérapie à base d'oxyde nitrique et applications biomédicales
JP5575489B2 (ja) 2007-03-23 2014-08-20 ゲノ エルエルシー 二酸化窒素（ｎｏ２）から酸化窒素（ｎｏ）への変換
AU2009209181B2 (en) 2008-01-28 2014-01-16 VERO Biotech LLC. Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
US8613958B2 (en) 2009-06-22 2013-12-24 Geno Llc Nitric oxide therapies
WO2011022652A1 (fr) 2009-08-21 2011-02-24 Novan, Inc. Gels topiques
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
AU2010321707B2 (en) 2009-11-20 2016-03-17 VERO Biotech LLC. Nitric oxide delivery system
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (fr) 2011-02-28 2012-09-07 Novan, Inc. Xérogels libérant de l'oxyde nitrique modifiés par des groupements s-nitrosothiols tertiaires et procédés d'utilisation associés

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5797887A (en) * 1996-08-27 1998-08-25 Novovasc Llc Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5691423A (en) * 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
HUP9801673A1 (hu) * 1998-07-24 2000-08-28 CYCLOLAB, Ciklodextrin Kutató-Fejlesztő Kft. Helyi vérbőséget fokozó gyógyszerkészítmények előállítása és alkalmazása

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5797887A (en) * 1996-08-27 1998-08-25 Novovasc Llc Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation

Also Published As

Publication number Publication date
WO2001015738A3 (fr) 2002-01-31
IL143305A0 (en) 2002-04-21
AU7101600A (en) 2001-03-26
CZ20011899A3 (cs) 2001-11-14
CA2353531A1 (fr) 2001-03-08
MXPA01005338A (es) 2003-07-14
WO2001015738A2 (fr) 2001-03-08

Similar Documents

Publication Publication Date Title
US7279176B1 (en) Nitric oxide-producing hydrogel materials
US7052711B2 (en) Nitric oxide-producing hydrogel materials
JP4841066B2 (ja) 酸化窒素生成ヒドロゲル物質
KR100266912B1 (ko) 조직접촉물질이며 방출조절운반체인 광중합성 생분해성 하이드로겔
WO2001015738A2 (fr) Materiaux hydrogels produisant du monoxyde d'azote
US5626863A (en) Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5410016A (en) Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
Sawhney et al. Bioerodible hydrogels based on photopolymerized poly (ethylene glycol)-co-poly (. alpha.-hydroxy acid) diacrylate macromers
Bohl et al. Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation
US7022343B2 (en) Controlled release of anti-arrhythmic agents
US6410044B1 (en) Crosslinkable macromers
EP1593377A1 (fr) Macromères réticulables portant des groupes initiateurs
US20020192182A1 (en) Polysaccharide-based polymerizable hydrogels
US20040138329A1 (en) Gels for encapsulation of biological materials
EP1586349A1 (fr) Libération contr lée d'agents anti-arrhythmiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010906

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010601;LT PAYMENT 20010601;LV PAYMENT 20010601;MK PAYMENT 20010601;RO PAYMENT 20010601;SI PAYMENT 20010601

17Q First examination report despatched

Effective date: 20030708

17Q First examination report despatched

Effective date: 20030708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071120